Stryker to acquire Inari Medical for $80/share cash, ~$4.9B equity value

STRYKER CORP

Stryker will pay $80 per share in cash for all outstanding Inari shares; total fully diluted equity value ~$4.9B.
Transaction expands Stryker into peripheral vascular segment, adding VTE thrombectomy solutions.
Boards of both companies unanimously approved; transaction expected to close by end of Q1 2025.
Tender offer requires majority share minimum tender, HSR waiting period expiration, and other customary conditions.
Inari (NARI) shareholders will receive $80/share; remaining shares acquired via second-step merger at same price.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.